Squibb Company (NYSE:BMY) today announced that the U.S. Food and
Drug Administration (FDA) has issued a Complete Response Letter (CRL)
regarding the New Drug Application (NDA) for daclatasvir, an NS5A
complex inhibitor, in combination with other agents for the treatment of
hepatitis C (HCV).
The initial daclatasvir NDA submitted to the FDA focused on its use in
combination with asunaprevir, an NS3/4A protease inhibitor.
for Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C investment picks